Search

Background Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. Methods BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Patients aged 18 years or older with moderate-to-severe hidradenitis suppurativa were randomly assigned 2:2:2:1 using interactive response technology (stratified by worst Hurley Stage at baseline and baseline systemic antibiotic use) to receive subcutaneous bimekizumab 320 mg every 2 weeks; bimekizumab 320 mg every 2 weeks to week 16, then every 4 weeks to week 48; bimekizumab 320 mg every 4 weeks to week 48; or placebo to week 16, then bimekizumab 320 mg every 2 weeks. The primary outcome was an hidradenitis suppurativa clinical response of at least 50%, defined as a reduction in total abscess and inflammatory nodule count of at least 50% from baseline with no increase from baseline in abscess or draining tunnel count (HiSCR50) at week 16. Efficacy analyses included all randomly assigned study patients (intention-to-treat population). Safety analyses included all patients who received at least one full or partial dose of study treatment in the safety set, and of bimekizumab in the active-medication set. These trials are registered at ClinicalTrials.gov, NCT04242446 and NCT04242498, and both are completed. Findings Patients for BE HEARD I were recruited from Feb 19, 2020, to Oct 27, 2021, and 505 patients were enrolled and randomly assigned. Patients for BE HEARD II were recruited from March 2, 2020, to July 28, 2021, and 509 patients were enrolled and randomly assigned. The primary outcome at week 16 was met in the group who received bimekizumab every 2 weeks using modified non, Background: Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. Methods: BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Patients aged 18 years or older with moderate-to-severe hidradenitis suppurativa were randomly assigned 2:2:2:1 using interactive response technology (stratified by worst Hurley Stage at baseline and baseline systemic antibiotic use) to receive subcutaneous bimekizumab 320 mg every 2 weeks; bimekizumab 320 mg every 2 weeks to week 16, then every 4 weeks to week 48; bimekizumab 320 mg every 4 weeks to week 48; or placebo to week 16, then bimekizumab 320 mg every 2 weeks. The primary outcome was an hidradenitis suppurativa clinical response of at least 50%, defined as a reduction in total abscess and inflammatory nodule count of at least 50% from baseline with no increase from baseline in abscess or draining tunnel count (HiSCR50) at week 16. Efficacy analyses included all randomly assigned study patients (intention-to-treat population). Safety analyses included all patients who received at least one full or partial dose of study treatment in the safety set, and of bimekizumab in the active-medication set. These trials are registered at ClinicalTrials.gov, NCT04242446 and NCT04242498, and both are completed. Findings: Patients for BE HEARD I were recruited from Feb 19, 2020, to Oct 27, 2021, and 505 patients were enrolled and randomly assigned. Patients for BE HEARD II were recruited from March 2, 2020, to July 28, 2021, and 509 patients were enrolled and randomly assigned. The primary outcome at week 16 was met in the group who received bimekizumab every 2 weeks using modified non-responder imputation; hi

Remote sensing of the bathymetry in shallow water of Tampa Bay is examined using the multi-spectral imagery from the Worldview-2 satellite. Utilizing the newly available yellow spectral band in a ratio algorithm, five ratio combinations are compared against a digital elevation model of Tampa Bay. Following the work of Stumpf et al. (2003) ratio algorithm and starting with the work of Loomis (2009) and Densham (2005), the yellow band was combined with the blue, green and red bands separately. These three ratio combination results were compared with the results of the more traditional blue/green combination and a green/red combination. Three transects lines were drawn in a shallow reef area in the north portion Tampa Bay, Florida on Mullet Key near Fort de Soto State Park. In water under 2 meters depth, the substrate contributions were significant in all ratio derived bathymetries. The addition of the yellow band provided more information about the bathymetry than the previous blue/green and green/red combinations by adding more combinations that utilized a reflectance level difference. The yellow band demonstrates less sensitivity to bottom type in two of the transect lines., http://archive.org/details/contributionstor109455772, Approved for public release; distribution is unlimited.

Remote sensing of the bathymetry in shallow water of Tampa Bay is examined using the multi-spectral imagery from the Worldview-2 satellite. Utilizing the newly available yellow spectral band in a ratio algorithm, five ratio combinations are compared against a digital elevation model of Tampa Bay. Following the work of Stumpf et al. (2003) ratio algorithm and starting with the work of Loomis (2009) and Densham (2005), the yellow band was combined with the blue, green and red bands separately. These three ratio combination results were compared with the results of the more traditional blue/green combination and a green/red combination. Three transects lines were drawn in a shallow reef area in the north portion Tampa Bay, Florida on Mullet Key near Fort de Soto State Park. In water under 2 meters depth, the substrate contributions were significant in all ratio derived bathymetries. The addition of the yellow band provided more information about the bathymetry than the previous blue/green and green/red combinations by adding more combinations that utilized a reflectance level difference. The yellow band demonstrates less sensitivity to bottom type in two of the transect lines., The original document contains color images.